Terumo and Quirem Medical, a commercial stage Dutch medical technology company that focuses on radioembolization, have announced that Terumo has made an equity investment in Quirem Medical.
Quirem Medical develops QuiremSpheres, next generation microspheres for the radioembolization treatment of liver cancer, which were developed by the University Medical Center (UMC) Utrecht, The Netherlands. Quiremspheres have received the European CE mark for quality and safety earlier this year.
Peter Coenen, president of Terumo Europe Interventional Systems, said: “QuiremSpheres could be a good fit with the product portfolio offered by Terumo to interventional oncologists and interventional doctors in their treatment of cancer patients.”
Jan Sigger, CEO of Quirem Medical, said: “We consider our holmium microspheres as ’the next generation microspheres for radioembolization’, as they can be visualised by both MRI scans and SPECT-CT, allowing customised treatment for each individual patient. We are confident that the investment by Terumo will accelerate our global expansion, reflecting our ambition to make our technology available to patients around the world.”
Maurice van den Bosch, head of Radiology University Centre Utrecht, commented: “We congratulate Quirem Medical and Terumo with their strategic partnership. Over the last 15 years the holmium microsphere technology, on which the QuiremSpheres are based, have been successfully developed within the University Medical Centre Utrecht. I am confident that our strategic collaboration with Quirem Medical will strongly benefit from the additional capabilities invested by Terumo”.
